leisure time -WSS

leisure time

author：comprehensive 2025-10-01 11:02:03 - browse：99

People in business and medical wardrobe in a table discussion — coverage from STAT — Adobe

R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private.

Private equity firm New Mountain Capital has offered to purchase R1 for $13.75 per share, or roughly $5.8 billion in cash, according to new financial disclosures filed Monday. New Mountain Capital is R1’s second-largest investor, owning nearly one-third of the company’s shares.

In response to the offer, R1 asked New Mountain Capital to “engage in good faith discussions” with its largest investor — a partnership between Ascension, the large Catholic hospital system, and private equity firm TowerBrook Capital Partners. New Mountain Capital has since held several in-person meetings with Ascension and TowerBrook throughout February, but maintained its original offer for R1. No deal has been finalized yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Pregnancy ages women, but effects reverse after delivery

WSS

Steward Health Care expansion into Malta flopped

There's no autism epidemic. It's an autism diagnosis epidemic

Asbestos ban is immediate, but health effects will linger for decades

Patient advocates debate FDA's accelerated approval process

Merck drug for rare lung condition set for approval in U.S.

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

hotspot

leisure time

hotspot

Activists slam private health insurers over coverage restrictions

What Kate Middleton's cancer revelation might teach the world

Activists slam private health insurers over coverage restrictions

U.K. officials, researchers try to ease path for bespoke genetic treatments

What does generative AI mean for health care? We asked experts

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

BioMarin wins approval for gene therapy to treat hemophilia A

Steward Health Care expansion into Malta flopped

Cancer drug shortages should be causing more outrage

FDA's naming rule on biosimilars has undermined competition

knowledge

What Kate Middleton's cancer revelation might teach the world

Pregnancy ages women, but effects reverse after delivery

Patient advocates debate FDA's accelerated approval process

FDA's naming rule on biosimilars has undermined competition

Steward Health Care expansion into Malta flopped

Pfizer, Moderna say biotech, pharma drug development is a sprint

entertainment

focus

Wikipedia

focus